Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. E. M. Wilkie, J. D. Chalmers, R. P. Smith, S. Schembri (Dundee, United Kingdom). Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis. Eur Respir J 2013; 42: Suppl. 57, 2339

Member's Comments

No comment yet.

Related content which might interest you: Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Diagnostic utility of surgical lung biopsies in elderly patients with interstitial lung diseases Source: International Congress 2015 – New insights into IIPs Year: 2015 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 Anti-parietal cell autoimmunity in IPF patients Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Prognostic significance of selected biomarkers in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease Source: International Congress 2014 – Sarcoidosis Year: 2014 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Comparison of physiological impairment in ILD patients with and without diagnostic IPF features Source: International Congress 2014 – ILDs 4 Year: 2014 Clinical profile of idiopathic pulmonary fibrosis with lung cancer Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Familial pulmonary fibrosis: Clinical-functional and radiological features Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Variation in mortality from interstitial lung disease by diagnosis Source: International Congress 2015 – IIPs: orphan Year: 2015 The clinical value of surgical lung biopsy in 166 patients with suspected interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Lung cancer in patients with idiopathic pulmonary fibrosis: Clinical characteristics and impact on survival Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013